Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared a post on LinkedIn:
“Thanks Julie Zhang from South China Morning Post (SCMP) for spotlighting the rapid growth of oncology drug development in China, specifically focusing on RAS-targeted cancer drugs. The global drug development landscape is rapidly changing.
Full article can be found here.”
Other articles about Oncology Drug on OncoDaily.